三博脑科9月23日获融资买入6029.94万元，融资余额6.37亿元

Core Viewpoint - Sanbo Brain Science experienced a decline of 1.39% in stock price on September 23, with a trading volume of 525 million yuan, indicating potential volatility in the stock market performance [1]. Financing Summary - On September 23, Sanbo Brain Science had a financing buy-in amount of 60.30 million yuan and a financing repayment of 63.94 million yuan, resulting in a net financing outflow of 3.64 million yuan [1]. - As of September 23, the total financing and securities lending balance for Sanbo Brain Science was 639 million yuan, with the financing balance accounting for 6.89% of the circulating market value, indicating a high level of financing activity [1]. - The company had a securities lending repayment of 1,300 shares and a securities lending sell-out of 12,700 shares, with a sell-out amount of 730,100 yuan, reflecting significant trading activity in the securities lending market [1]. Company Performance - As of June 30, the number of shareholders for Sanbo Brain Science reached 43,200, an increase of 14.69% compared to the previous period, while the average circulating shares per person decreased by 12.81% to 3,725 shares [2]. - For the first half of 2025, Sanbo Brain Science reported an operating income of 827 million yuan, representing a year-on-year growth of 17.54%, and a net profit attributable to shareholders of 69.70 million yuan, up 4.60% year-on-year [2]. Dividend and Shareholding Structure - Since its A-share listing, Sanbo Brain Science has distributed a total of 45.10 million yuan in dividends [3]. - As of June 30, 2025, the second-largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 4.81 million shares as a new shareholder, while the Southern Zhongzheng 1000 ETF increased its holdings by 249,800 shares to 1.33 million shares [3].